GoodRx Q2 revenue $189.7M beats guidance; Adj. EBITDA $53.5M

GoodRx Holdings, Inc.

2023-Q2 EPS reported $0.13 revenue$373,663,000

Total revenue $189.7M, exceeding previously announced guidance; net income $58.8M (includes $46.7M tax benefit).
Adjusted EBITDA $53.5M (28.2% margin), also above guidance; adjusted net income $28.4M.
Prescription transactions revenue and volume returned to year-over-year growth.
Over 500,000 prescribers engaged via Provider Mode; over 7M consumers of prescription offerings.
New program with CVS Caremark and expanded direct pharmacy contracts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GoodRx Holdings, Inc. reported the three and six months ended June 30, 2023 results: revenue $189.7 million, net income $58.8 million.

Period: the three and six months ended June 30, 2023
Revenue: $189.7 million
Net income: $58.8 million
Result: reported results

Exact text from the filing

Total revenue of $189.7 million, exceeding previously announced guidance • Net income of $58.8 million

View on SEC.gov

Browse all earnings releases →

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-028384

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.